Answers are grounded in this paper and cite their sources.
Genome editing has moved from an experimental research tool to a clinically relevant biotechnology, but its governance remains difficult because the technology itself continues to evolve. Existing debates have often focused on the ethical permissibility of specific applications, especially heritable human genome editing. This review argues that the broader challenge is one of regulatory design: legal and institutional frameworks must govern a field whose modalities, delivery systems, risks, and evidentiary standards are changing. Focusing on human biomedical genome editing, the article examines how scientific developments such as CRISPR-Cas9, base editing, and prime editing expose limitations in current international, national, and institutional governance arrangements. It then analyzes precautionary, innovation-permissive, risk-based, responsive, adaptive, and anticipatory approaches, arguing that each captures part of the problem but remains incomplete when the object of regulation is dynamic. To address this gap, the article proposes technology-responsive regulation (TRR) as a legal-regulatory framework built around adaptive regulatory capacity, scientific-institutional integration, and multilevel coordination. TRR organizes familiar governance tools, including periodic review, differentiated categorization, scientific advice, registries, public engagement, enforcement, and international coordination, around the task of maintaining accountable oversight as genome editing changes. Responsible governance requires not only stronger rules, but institutions capable of revising them without losing legality, accountability, or public trust.
No takes yet. Share an insight, caveat, or question.
Bao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: